CTRI/2016/02/006636尚未招募4 期
â??Post Marketing, Non-Randomized Open label Single Arm, Prospective study to evaluate the clinical outcomes in patients implanted with a foldable, hydrophobic acrylic, natural yellow, single piece, injectable, Toric Intraocular Lens - toric iol
ethradhama super speciality eye hospital0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Unilateral/Bilateral cataract
- •Patient must have preoperative regular corneal astigmatism from 0.75 to 2.50 D as per corneal topography or keratometry
- •Patients who have and will attend all follow-up appointments
- •Patients must sign and be given a copy of the written Informed Consent form
排除标准
- •Preoperative ocular pathology
- •Presence of irregular corneal astigmatism
- •Ocular co-morbidities affecting visual outcomePrevious intra ocular or corneal surgery
- •Corneal Opacities
- •Ophthalmic diseases such as pseudoexfoliation, glaucoma, traumatic cataract corneal scars and other co-morbidity that could affect capsule bag stability
- •Pre-existing corneal astigmatism lesser than 0.75 D Pre-existing retinal disease
研究者
相似试验
尚未招募
4 期
Post-marketing observational study to compare the efficacy and safety of ImmulinaTM-800 as add-on therapy against standard of care in the management of patients with Chronic Obstructive Pulmonary Disease.CTRI/2019/07/020005Wockhardt Ltd
已完成
4 期
A post marketing surveillance study to check safety and tolerability of a nasal pack (VELNEZ) after a nasal surgery in pediatric patients.CTRI/2023/02/049831Datt Mediproducts Pvt. Ltd.
进行中(未招募)
1 期
Astudy to investigate the safety and tolerability of octaplas™ in the management of pediatric patients who require therapeutic plasma exchange.Therapeutic plasma exchangeEUCTR2020-000650-10-Outside-EU/EEAOctapharma41
招募中
4 期
A study of stempeucel® in patients with critical limb ischemia due to occlusive inflammatory condition of arteries and veinsCTRI/2018/02/011839Stempeutics Research Pvt Ltd
尚未招募
不适用
Clinical Study on Beta Glucan (AFO 202) to treat Parkinsons Disease.CTRI/2022/05/042498ichiIn Bio Sciences Pvt Ltd
